asthma

Sep 01, 2025

Asthma: A Global Burden Driving Therapeutic Breakthroughs Asthma is a chronic inflammatory condition of the airways characterized by variable symptoms including wheezing, shortness of breath, chest tightness, and cough. It involves underlying airway inflammation, bronchial hyperresponsiveness, and reversible air...

Aug 18, 2025

“We have inhalers that can save lives in seconds and biologics that can change the course of the disease—so why are millions still wheezing in emergency rooms (ERs)?” A Global Paradox in Respiratory Health Asthma today stands at the intersection of remarkable scientific progress and sobering real-world stagna...

Oct 08, 2024

FDA Approves Perioperative OPDIVO Plus Chemotherapy for Resectable NSCLC The FDA has granted approval to Bristol Myers Squibb’s OPDIVO (nivolumab) for the treatment of adult patients with resectable non-small cell lung cancer (NSCLC), specifically targeting tumors that are 4 cm or larger or node-positive and hav...

Jun 26, 2024

Asthma is a major noncommunicable disease that impacts both children and adults, and it is the most prevalent chronic condition among children. In 2019, ~262 million individuals were impacted by asthma, resulting in 455K deaths all over the world. More than 27 million individuals in the United States suffer from...

Jan 24, 2024

Technological evolution has significantly transformed Airway Management Devices in recent years, ushering in a new era of efficiency, precision, and patient safety. Advances in materials, design, and manufacturing processes have led to the development of more sophisticated devices. Moreover, the incorporation of hi...

Jan 23, 2024

Opdivo in Combination with CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Bristol Myers Squibb and Exelixis, Inc. have released the four-year follow-up findings from the CheckMate -9ER trial, which investiga...

Sep 12, 2022

Key Highlights Tezspire (tezepelumab) with no phenotypic (eosinophilic or allergic) or biomarker restriction will be the new game-changer in the severe asthma marketDepemokimab is an excellent market replacement for GSKs’ Nucala as of its improved binding affinity and longer duration of action as a single doseNo...

Mar 22, 2022

NHS Grants Fast Track Access to Takeda’s Exkivity Takeda has secured UK approval for its lung cancer therapy Exkivity, with an NHS access deal that could see it prescribed to patients within the next few weeks. The Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorisa...

Feb 01, 2022

Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will ha...

Jan 05, 2022

Although COVID-19 continued to dominate headlines in 2021, pharmaceutical companies did not cease developing new treatments this year. The US Food and Drug Administration maintained a rapid rate of new drug approvals this year, all while managing the urgent examination of COVID-19 tests, treatments, and vaccines un...